Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Bevacizumab Biosimilars Market Expected to Be in 2029?

The market size of bevacizumab biosimilars has seen a robust growth in the recent past. It is projected to increase from $1.53 billion in 2024 to $1.64 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%. The significant growth during the historic period can be credited to factors like patent expiry, efforts to control healthcare costs, rising prevalence of cancer, market competitiveness, patient accessibility, affordability, and the acceptance of biosimilars.

The market size of bevacizumab biosimilars is forecasted to experience significant expansion in the coming years, growing to “$2.23 billion by 2029 at a compound annual growth rate (CAGR) of 7.9%. A number of factors are driving growth during the forecast period including increased cancer treatment demand, skills in biosimilar development, pressures on the healthcare system, the regulatory environment for biosimilars, and biosimilar interchangeability. Key trends predicted during the forecast period encompass collaborative efforts and partnerships, advancements in regulations and approvals, innovation in biosimilar development, strategies for market access, and biosimilar lifecycle management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Are The Contributors To Demand In The Bevacizumab Biosimilars Market?

The increasing rates of cancer diagnoses are anticipated to fuel the advancement of the bevacizumab biosimilar market in the future. The incidence of cancer pertains to the emergence of new instances of cancer in a certain population within a specific timeframe. Bevacizumab, a biological inhibitor of tumor angiogenesis, can cause tumors to recede and hinder their growth, and is as effective and safe as its reference biologic equivalent in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. As an example, in October 2024, the National Health Service (NHS) in the UK reported 346,217 new cancer diagnoses, averaging 948 cases daily in 2022, representing a 5% growth in comparison to the 329,664 diagnoses in 2021. There was also a 7% elevation in cancer diagnoses, escalating from 167,917 to 180,877 in 2022. Consequently, the escalating prevalence of cancer is a significant driver for the bevacizumab biosimilars market.

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

Which Emerging Trends And Strategic Shifts Are Shaping The Bevacizumab Biosimilars Market?

In the bevacizumab biosimilars market, product innovation is becoming a significant trend. Key players in the market are focusing on developing unique products to solidify their market position. An example of this was seen in May 2022 when Viatris and Biocon Biologics, both US-based pharmaceutical companies, introduced a biosimilar named Abevmy, a bevacizumab biosimilar to Roche’s Avastin. Health Canada has given approval to Abevmy for application in four oncology areas. The product, which is a synthesized humanized monoclonal antibody (MA), effectively binds to and hampers the biologic impact of human vascular endothelial growth factor (VEGF), ensuring that it provides efficacy, safety, and quality equivalent to the reference biologic.

Who Are The Top-Ranked Companies In The Bevacizumab Biosimilars Market Today?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

How Is Bevacizumab Biosimilars Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model